A Framingham genome testing practice announced Wednesday it has partnered with Boston genomic intelligence firm FDNA to help diagnose rare genetic disorders.
Genome testing company Service Variantyx will use FDNA’s Face2Gene application which will, according to a press release, enable clinicians around the world to send information about phenotypes, syndromes and genes correlating with a patient’s facial and clinical analysis.
The application uses facial analysis, deep learning and artificial intelligence to improve and accelerate diagnostics and therapeutics, according to a press release.
The application will provide a more complete phenotypic picture, Variantyx CEO Haim Neerman said.
Financial terms of the partnership were not disclosed.
